UK-based clinical genomics software developer Congenica has closed a series B round of undisclosed size after securing additional funding from investors including genomics technology provider BGI Genomics and healthcare services provider Healthlink.
Investment platform Future Planet Capital was also among the new investors, adding to the £8m ($10m) first tranche, which closed in February this year with backing from Cambridge Innovation Capital (CIC), Amadeus Capital Partners and Parkwalk Advisors.
Congenica has built a software platform called Sapientia that analyses data on genome-scale DNA in order to compile a detailed diagnostic report for each patient that can be used to help inform clinical decisions for rare genetic diseases.
Healthlink’s clinical diagnostics lab, UniteGen, and BGI have both signed contracts to use Sapientia in their respective operations. Healthlink participated in the round through its Healthlink Capital subsidiary.
Tom Weaver, Congenica’s CEO, said: “This additional investment enhances our ability and commitment to deploy our software platform to international markets. Particularly China, where we have established a scalable partnering model to transform the clinical genetic testing market.
“Genomic technology will be central to the next generation healthcare system that is evolving rapidly in China and we are delighted to be working with strategic partners, both at the financial and commercial level, who are at the forefront of that change and committed to the benefits it will bring to patients.”
Congenica had previously raised £3.2m in funding, securing £1m in seed capital from CIC in late 2014 before adding £2.2m in series A funding from CIC and Amadeus the following year.